3D Ultrasound Validation for Measuring Stomach Volume (3DUSstomach)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00588224
Recruitment Status : Completed
First Posted : January 8, 2008
Last Update Posted : July 22, 2009
Information provided by:
Mayo Clinic

Brief Summary:
The goal is to study the accuracy of 3-dimensional ultrasound (which does not involve radiation) to measure the size of the stomach, comparing it with a previously validated method that involves radiation. This will make it possible to check the stomach function of children without exposing them to radiation. A second goal is to measure the size of the stomach and the effect of a standard meal on stomach volume in adolescent boys and girls.

Condition or disease Intervention/treatment
Healthy Other: 3D ultrasound

Detailed Description:

Specific Aims

  1. To compare the fasting and postprandial volumes measured by 99mTc- SPECT (standard test) and 3-D ultrasound in 12 healthy adults in order to test latter's external validity
  2. To assess the performance characteristics of 3-D ultrasound for the measurement of gastric volumes during fasting and in response to a standard meal, specifically, the intra- and inter-individual coefficient of variation in 12 healthy adults who undergo two estimations of fasting and postprandial volumes
  3. To develop normative data for fasting and postprandial gastric volumes in 24 asymptomatic adolescents.

Study Design

The study will be conducted in 2 parts: first, 12 healthy adults will undergo SPECT and 3-D ultrasound in random order (aim 1); one week after the first ultrasound examination, a second Ultrasound examination will be conducted in all participants (aim 2) In the second part, 24 adolescents (12 in each gender, 12 aged 13-15, 12 aged 16-18)) will undergo a single determination of fasting and postprandial gastric volumes during fasting and post-prandially. The methods and validation of the SPECT study have been previously published (2). Three D ultrasonography will be conducted using state of the art equipment following methods published in the literature. (3)

The study will screen 80 healthy adults or adolescents in order to enroll 12 healthy adulkts for the first two aims, and 24 adolescent healthy subjects for the third aim.

For subjects in group 1, the order of SPECT and 3D- ultrasound tests will be randomized.

The randomization assignments will be made according to a pre-study schedule prepared by the Section of Biostatistics. Medical investigators will be blinded to assignment, allocation will be concealed

Study Type : Observational
Actual Enrollment : 36 participants
Time Perspective: Prospective
Official Title: Validation and Application of 3-dimensional Ultrasound for Measurement of Gastric Volumes in Healthy Subjects
Study Start Date : October 2007
Actual Primary Completion Date : June 2008
Actual Study Completion Date : June 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ultrasound
U.S. FDA Resources

Group/Cohort Intervention/treatment
Other: 3D ultrasound
measurement of stomach volume by 3D ultrasound
Other: 3D ultrasound
measurement of stomach volume by 3D ultrasound

Primary Outcome Measures :
  1. Fasting and Postprandial gastric volumes measured by 3D ultrasonography in adults and adolescents [ Time Frame: one month ]

Secondary Outcome Measures :
  1. Intra and inter-individual COV in adults for fasting and postprandial volumes [ Time Frame: one month ]
  2. Accuracy of 3D-ultrasonography in measurement of fasting and posprandial volume using Bland-Altman plot [ Time Frame: one month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   13 Years to 65 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
ealthy adolescents and adults: The study will screen up to 80 healthy adults or adolescents in order to enroll 12 healthy adults for the first two aims, and 24 adolescent healthy subjects for the third aim

Inclusion Criteria:

  1. Age: 13-65 years
  2. Body mass index (BMI): 18 to 32 (exept in adolescents)
  3. Negative urine pregnancy test for women of childbearing potential
  4. Absence of gastrointestinal symptoms (abridged Bowel Disease Questionnaire)
  5. Signed informed consent

Exclusion Criteria:

  1. Subjects with body mass index (BMI) of less than 18 or more than 32.
  2. Structural or metabolic diseases/conditions that affect the gastrointestinal system, or functional gastrointestinal disorders. For screening, the Bowel Disease Questionnaire will be used to exclude subjects with irritable bowel syndrome.
  3. Use of drugs or agents within the past 2 weeks that alter GI transit including laxatives, magnesium or aluminum-containing antacids, prokinetics, erythromycin, narcotics, anticholinergics, tricyclic antidepressants, SSRI and newer antidepressants.

    NOTE: Low stable doses of thyroid replacement, estrogen replacement, low dose aspirin for cardioprotection, and birth control pills or depot injections are permissible.

  4. Female subjects who are pregnant or breast feeding.
  5. Females must be either surgically sterilized, postmenopausal (>12 months since last menses) or, if of childbearing potential, using reliable methods of contraception as determined by the physician (single-barrier methods alone and rhythm methods are not acceptable).
  6. Clinical evidence (including physical exam and ECG) of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric, or other disease that interfere with the objectives of the study. Any candidate participants with such disorder mentioned will be referred to their general physician.
  7. Symptoms of a significant clinical illness in the preceding two weeks.
  8. Participation in another clinical study within the past 30 days.
  9. Subjects who are considered by the investigator to be alcoholics not in remission or known substance abusers.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00588224

Sponsors and Collaborators
Mayo Clinic
Principal Investigator: Michael L Camilleri, MD Mayo Clinic

Additional Information:
Responsible Party: Michael Camilleri MD, Mayo Clinic Identifier: NCT00588224     History of Changes
Other Study ID Numbers: 07-005231
First Posted: January 8, 2008    Key Record Dates
Last Update Posted: July 22, 2009
Last Verified: July 2009

Keywords provided by Mayo Clinic:
3 dimensional ultrasonography
healthy volunteers